Nonsteroidal anti-inflammatory drugs and endometrial carcinoma mortality and recurrence

Journal of the National Cancer Institute

Volumn 109, Issue 3, 2017, Pages

  Brasky, Theodore M ^a   Felix, Ashley S ^a,c   Cohn, David E ^b   McMeekin, D Scott ^d   Mutch, David G ^e   Creasman, William T ^f   Thaker, Premal H ^e   Walker, Joan L ^d   Moore, Richard G ^g   Lele, Shashikant B ^h   Guntupalli, Saketh R ⁱ   Downs, Levi S ^j   Nagel, Christa I ^k   Boggess, John F ^l   Pearl, Michael L ^m   Ioffe, Olga B ⁿ   Park, Kay J ^o   Ali, Shamshad ^h   Brinton, Louise A ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g BROWN UNIVERSITY   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m STONY BROOK UNIVERSITY   (United States)

ⁿ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CAUSE OF DEATH; CONTROLLED STUDY; DRUG USE; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MIDDLE AGED; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENCE RISK; ADENOCARCINOMA; CANCER GRADING; CARCINOSARCOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; EPIDEMIOLOGY; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS; RISK FACTOR; TIME FACTOR; TUMOR RECURRENCE; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PROGNOSIS; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 85017018339     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw251     Document Type: Article

References (54)

1. Wallace AE, Gibson DA, Saunders PT, et al. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010;206(2):141-157.
2. Dossus L, Becker S, Rinaldi S, et al. Tumor necrosis factor (TNF)-alpha, soluble TNF receptors and endometrial cancer risk: The EPIC study. Int J Cancer. 2011; 129(8):2032-2037.
3. Dossus L, Rinaldi S, Becker S, et al. Obesity, inflammatory markers, and endometrial cancer risk: A prospective case-control study. Endocr Relat Cancer. 2010;17(4):1007-1019.
4. Brasky TM, Moysich KB, Cohn DE, et al. Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. Gynecol Oncol. 2013;128(1):113-119.
5. Neill AS, Nagle CM, Protani MM, et al. Aspirin, nonsteroidal antiinflammatory drugs, paracetamol and risk of endometrial cancer: A casecontrol study, systematic review and meta-analysis. Int J Cancer. 2013;132(5): 1146-1155.
6. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-606.
7. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-658.
8. Ng K, Meyerhardt JA, Chan AT, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107(1):345.
9. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24): 2563-2571.
10. Coghill AE, Newcomb PA, Campbell PT, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut. 2011;60(4):491-498.
11. Coghill AE, Newcomb PA, Chia VM, et al. Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer. 2011;104(5):763-768.
12. Karageorgi S, Hankinson SE, Kraft P, et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer. 2010;126(1):208-216.
13. Zervoudakis A, Strickler HD, Park Y, et al. Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst. 2011;103(10): 826-834.
14. Kilic G, Gurates B, Garon J, et al. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol. 2005;26(3):271-274.
15. Keser SH, Gul AE, Barisik NO, et al. The relationship of COX-2 expression with estrogen receptor, progesterone receptor and prognostic parameters in endometrial carcinomas. J Obstet Gynaecol Res. 2010;36(3):560-566.
16. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: Tissue microarray analysis. Am J Obstet Gynecol. 2005;192(4):1262-1271; discussion 1271-1273.
17. Gates MA, Tworoger SS, Eliassen AH, et al. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1033-1041.
18. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15(2):485-497.
19. Henderson BE, Ross RK, Pike MC, et al. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42(8):3232-3239.
20. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129(2):277-284.
21. Zaino RJ. FIGO staging of endometrial adenocarcinoma: A critical review and proposal. Int J Gynecol Pathol. 2009;28(1):1-9.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:13.
23. Zhou B, Fine J, Laird G. Goodness-of-fit test for proportional subdistribution hazards model. Stat Med. 2013;32(22):3804-3811.
24. Vittinghoff E, Glidden D, Shiboski SC, et al. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. 2nd ed. New York: Springer; 2012.
25. Brueggemeier RW, Diaz-Cruz ES, Li PK, et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol. 2005;95(1-5):129-136.
26. Ebert AD, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: New questions-old answers? Eur J Obstet Gynecol Reprod Biol
27. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase E-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319-1323.
28. Brasky TM, Liu J, White E, et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative. Int J Cancer. 2014;135(8):1869-1883.
29. Danforth KN, Gierach GL, Brinton LA, et al. Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res (Phila). 2009;2(5):466-472.
30. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2010;19(2):435-442.
31. Viswanathan AN, Feskanich D, Schernhammer ES, et al. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008; 68(7):2507-2513.
32. Setiawan VW, Matsuno RK, Lurie G, et al. Use of nonsteroidal antiinflammatory drugs and risk of ovarian and endometrial cancer: The multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1441-1449.
33. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77-85.
34. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial. JAMA. 2005;294(1):47-55.
35. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379(9826):1602-1612.
36. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Inst. 2009; 101(4):256-266.
37. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.
38. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5): 518-527.
39. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591-1601.
40. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis. Gut. 2015; 64(9):1419-1425.
41. Ye XF, Wang J, Shi WT, et al. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: A meta-analysis of observational studies. Br J Cancer. 2014;111(11):2172-2179.
42. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081-2087.
43. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Association between statin use and endometrial cancer survival. Obstet Gynecol. 2015;126(1): 144-150.
44. Matsuo K, Cahoon SS, Yoshihara K, et al. Association of low-dose aspirin and survival of women with endometrial cancer. Obstet Gynecol. 2016;128(1): 127-137.
45. Yang HP, Meeker A, Guido R, et al. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes Control. 2015;26(12):1729-1736.
46. Merritt MA, Strickler HD, Einstein MH, et al. Insulin/IGF axis in human endometrium and associations with cancer risk factors. Cancer Causes Control. 2016;27(6):737-748.
47. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9(1):1-19.
48. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 1995;19(6):666-674.
49. Nordal RR, Kristensen GB, Stenwig AE, et al. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol. 1997;67(3):316-321.
50. McCluggage WG. Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinomas?. J Clin Pathol. 2002;55(5):321-325.
51. Felix AS, Cook LS, Gaudet MM, et al. The etiology of uterine sarcomas: A pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108(3):727-734.
52. Zelmanowicz A, Hildesheim A, Sherman ME, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol. 1998;69(3):253-257.
53. Bland AE, Stone R, Heuser C, et al. A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer. 2009;19(2):261-265.
54. Ward KK, Shah NR, Saenz CC, et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012; 126(2):176-179.